Michelle R. Padget

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Erika J. Lampert, Alexandra S. Zimmer, Michelle R. Padget et al. · Clinical Cancer Research · 2020 · 209 citations · Full text

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele

Caroline Jochéms, James W. Hodge, Massimo Fantini et al. · Oncotarget · 2016 · 180 citations · Full text

Lymphocyte Development, Immunology, Immune Regulation +27

Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer

So Jin Park, Wenda Ye, Roy Xiao et al. · Oral Oncology · 2019 · 174 citations · Full text

Neck Cancer, Malignant Disease, Preclinical Models +12

Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile

Kimberly Cramer-Morales, Margaret Nieborowska-Skorska, Kara Scheibner et al. · Blood · 2013 · 143 citations · Full text

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations

Kellsye P. Fabian, Michelle R. Padget, Renee N. Donahue et al. · Journal for ImmunoTherapy of Cancer · 2020 · 143 citations · Full text